Bisabolol (unknown isomer) is best treated as an unresolved archive identity rather than a single precisely characterized molecule. Live source review supports the broader bisabolol family as a sesquiterpene alcohol group with multiple stereoisomers, recurring cosmetic-use safety data, and penetration-enhancing behavior, but the specific isomer in this archive slot was not identified in the underlying oil source. For AromaForge, this record should emphasize identity ambiguity first and only discuss broader bisabolol-class evidence with careful labeling.
Chemical identity and composition
The Cosmetic Ingredient Review states that bisabolol exists in both alpha- and beta-configurations and possesses four stereoisomers, while its 2015 re-review notes that the cosmetic-dictionary entry refers specifically to the alpha configuration and that much of the historical safety literature centers on (-)-alpha-bisabolol. PubChem resolves the generic name Bisabolol to CID 1549992 with formula C15H26O, but that database resolution is more specific than the archive's current oil-level identification, which did not assign the isomer.
Aroma and practical use
- Use the recorded soft woody, sweet, floral, balsamic descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
The 2015 Cosmetic Ingredient Review re-review reaffirmed that bisabolol is safe as used in cosmetic formulations and summarized earlier toxicology, genotoxicity, and clinical sensitization data for the broader ingredient.
The CIR document states that bisabolol exists as multiple stereoisomers, notes dermal absorption and penetration-enhancing behavior, and summarizes the earlier conclusion that bisabolol was safe as used in cosmetics.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
The same CIR review summarized a 28-day rat dermal study with a no-observable-adverse-effect level of 200 mg/kg/day for a 4% alpha-bisabolol solution and a clinical product test in which 0.1% bisabolol was negative for sensitization.
Those findings apply to studied bisabolol material rather than an unresolved isomer, but they provide the best accessible public safety anchor for this placeholder record.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
Do not imply that this archive slot inherits all data from (-)-alpha-bisabolol or other named stereoisomers; the source identification did not resolve the isomer.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
The strongest public safety data found in this pass come from broader bisabolol cosmetic review literature rather than from constituent-specific studies on an unknown isomer.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
Because bisabolol-class materials can enhance dermal penetration, finished-formula context matters when combining them with other actives.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
penetration_enhancement_in_bisabolol_class
The CIR bisabolol safety review states that bisabolol is well absorbed after dermal application and that an in vitro study found penetration-enhancing behavior, but that evidence pertains to characterized bisabolol material rather than this unresolved isomer slot.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
no_isomer_specific_mechanism_verified
No public source located in this pass verified a mechanism tied specifically to the unresolved bisabolol isomer represented here.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- No authoritative public source located in this pass identified which bisabolol stereoisomer is present in the archive's source oil.
- No single CAS was assigned here because using one would imply a more precise identification than the source supports.
- Constituent-specific efficacy or toxicology for this unresolved isomer was not verified beyond broader bisabolol-class literature.
- Safety-verification pass (2026-07-13, worker c5): confirmed no IFRA Standard exists for an unresolved/generic bisabolol isomer; the only applicable IFRA Standard (alpha-Bisabolol, CAS 515-69-5, Amendment 49) is isomer-specific and not verified as a match for this archive slot, so the prior dermal_limit_pct of 20 (inherited from that standard without confirmation) has been corrected to null rather than implying a verified isomer-specific limit.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.